Since somatostatin is known to influence renal function and the administration of somatostatin analogues inhibit the GH-IGF-1 related decline in renal function in T2DM, increased plasma NT-proSST concentrations may reflect a compensatory increase in somatostatin in order to prevent progression of renal decline among patients with T2DM [30-32]. This evidence concerns the gene GH1 and type 2 diabetes mellitus.